Blood loss is the leading cause of preventable death both for civilians and the military. The probability of death increases approximately 1% for each 3-minute delay to definitive control, emphasizing the need to rapidly control bleeding. Uncontrollable hemorrhage induces a coagulopathy marked by three major characteristics – loss of blood volume, inability to form clots, and the rapid breakdown of clots that do form. Whether the patient is a soldier, a patient on Coumadin, or a hemophiliac, the treatment needed to avert blood loss remains the same.
Cayuga Biotech is focused on developing a treatment for uncontrollable hemorrhage using nanotechnology and biomaterials. Cayuga seeks to translate founder Damien Kudela’s PhD thesis - on using nanomaterials to improve treatment for uncontrollable hemorrhage – into clinical use. Cayuga’s team includes leading experts in the fields of pharmaceutical development, materials for hematological control, and regulatory development. The tea...
Blood loss is the leading cause of preventable death both for civilians and the military. The probability of death increases approximately 1% for each 3-minute delay to definitive control, emphasizing the need to rapidly control bleeding. Uncontrollable hemorrhage induces a coagulopathy marked by three major characteristics – loss of blood volume, inability to form clots, and the rapid breakdown of clots that do form. Whether the patient is a soldier, a patient on Coumadin, or a hemophiliac, the treatment needed to avert blood loss remains the same.
Cayuga Biotech is focused on developing a treatment for uncontrollable hemorrhage using nanotechnology and biomaterials. Cayuga seeks to translate founder Damien Kudela’s PhD thesis - on using nanomaterials to improve treatment for uncontrollable hemorrhage – into clinical use. Cayuga’s team includes leading experts in the fields of pharmaceutical development, materials for hematological control, and regulatory development. The team of PhD scientists is bolstered by business advisors who have over 80 years experience in biotech and have overseen over $1B in exits as CEO of four different companies. Cayuga’s regulatory advisor served for 23 years as a toxicologist and pharmacologist at the FDA.
Cayuga’s proprietary drug marks a paradigm shift in the treatment of bleeding. Cayuga uses innovative platelet-like nanoparticles to accelerate the body’s natural coagulation process. Rather than the drug targeting the body, the body targets Cayuga’s drug to promote clotting where it is needed without initiating clotting in healthy vessels. Cayuga has run multiple animal studies that have demonstrated that the therapy reduces bleeding time 90%, reduces blood loss 40 %, and does not increase the risk for unwanted clotting.
Several systemic blood clotting agents including Novoseven, Andexxa, and Kcentra are expected to surpass $1B in peak annual sales. To date, Cayuga has raised $1.8MM from DARPA and the US Army to develop our treatment for the battlefield. We are currently seeking a seed round to fund development for an orphan rare bleeding disorder that will significantly reduce the time and money needed for clinical trials. Once approved for either indication, Cayuga will pivot to indications whose markets should support broad sales, specifically anticoagulant reversal. Demonstration of safety in patients will provide a competitive edge in these multi-million patient markets.
More information

Employees

Damien Kudela
Admin
Damien Kudela CEO PhD turned entrepreneur. Inventor of Cayuga's drug.
Nathan Ogden
Admin